Latest News

We feel now is a pretty good time to analyse LifeStance Health Group, Inc.'s ( NASDAQ:LFST ) business as it appears the...

On October 22, 2025, DataVault AI, Inc. and Wellgistics Health, Inc. announced a non-binding letter of intent to integrate manufacturer-to-patient blockchain-enabled smart contracts into Wellgistics' prescription drug infrastructure, aiming to fully digitize tracking from script to fulfillment across more than 6,500 pharmacies nationwide. A unique aspect of this partnership is its focus on leveraging AI agents and digital routing tools to optimize prescription drug services while enhancing...

Companhia de Saneamento Básico do Estado de São Paulo - SABESP (BVMF:SBSP3) has had a great run on the share market...

Thinking about what to do with TKO Group Holdings stock? If you own shares or are sizing up an entry, you’re probably weighing not only its impressive run but also wondering whether there is real value left or just excitement. TKO has certainly been hard to ignore. The stock has surged 63.6% over the past year, and it is up 30.9% year-to-date, showing strength most markets would envy. Even after a recent dip of 1.3% in the last week and a 6.1% slide over the last month, it is clear that the...

Sify Technologies (NasdaqCM:SIFY) remains in the red, with losses deepening at an average rate of 60.8% per year over the past five years. Although the company trades at a premium price-to-sales ratio of 1.9x compared to the US Telecom industry’s 1.2x average and its peers at 1.4x, forecasts call for a turnaround. Earnings are projected to surge 158.14% per year, with profitability expected within three years and revenue tipped to grow 30.1% annually, well ahead of the 10.1% US market pace...

MTU Aero Engines AG recently reported third-quarter results, posting group sales of €2.13 billion and net income of €250 million, both higher than the previous year, while also reaffirming its full-year 2025 revenue outlook between €8.6 billion and €8.8 billion. The company's leadership highlighted a mid-twenties percentage increase in adjusted core income, robust demand for commercial engines and maintenance, and plans to begin final assembly and delivery of its newly certified GTF...

If you’ve found yourself eyeing Graham Holdings after its most recent moves, you’re not alone. Whether you’re considering holding, trimming, or jumping in fresh, the stock’s behavior lately has gotten plenty of investors talking. Despite facing a pullback of 13.7% over the last 30 days, which might have rattled less seasoned hands, Graham Holdings is still up an impressive 18.1% year to date and 33.8% over the past year. Step back further, and you see gains of 67.4% across three years and...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Over the past year, many Standard Chartered PLC ( LON:STAN ) insiders sold a significant stake in the company which may...

Kinatico (ASX:KYP) has drawn investor attention with its recent pivot to software as a service, marked by the launch of ComplianceX. The company is targeting underserved small and mid-sized enterprises through a freemium-led model. See our latest analysis for Kinatico. Kinatico’s share price has soared 175% since the start of the year, with momentum accelerating in recent weeks. The stock saw a 1-day gain of 10% and a 30-day share price return of over 24%. Over the past year, total...

Key Insights Institutions' substantial holdings in Mpac Group implies that they have significant influence over the...

Röko (OM:ROKO B) posted earnings growth of 3.9% in its latest results, noticeably slower than its five-year average of 29.9% per year. Revenue is forecast to increase at 3.3% annually, underperforming the Swedish market’s expected 3.8%. Net profit margin edged down to 11.2% from last year’s 11.6%. Investors now have to balance Röko’s track record of consistent profit and revenue growth with a recent moderation in momentum and profit margins. See our full analysis for Röko. Next, we will stack...

Ventyx Biosciences recently announced positive topline results from its Phase 2 clinical trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP and IL-6 in patients with obesity and cardiovascular risk factors. An interesting insight from the study is that VTX3232 achieved a robust safety and tolerability profile, both as a standalone therapy and in combination with semaglutide, highlighting its potential as a new oral anti-inflammatory option in...

If you’ve been eyeing CECO Environmental and wondering whether it’s time to get in, stay patient, or take wins off the table, you’re not alone. This stock has been quietly (and not so quietly) rewarding attentive investors with some eye-popping returns. Just check out the numbers: up 6.7% over the past week, 5.9% in the last month, and an astonishing 66.1% so far this year. Zoom out further, and the gains are even more impressive: nearly 95% for the past year and a staggering 637% over the...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

When close to half the companies in Austria have price-to-earnings ratios (or "P/E's") above 16x, you may consider...

With a price-to-earnings (or "P/E") ratio of 13.1x Vesuvius plc ( LON:VSVS ) may be sending bullish signals at the...

If you are weighing your next move with Old National Bancorp, you are certainly not alone. Investors are taking note as this regional bank’s stock has delivered a rollercoaster of returns lately. In just the past week, shares have climbed 6.0%, a sharp turnaround from last month’s dip of almost 5%. With a strong 15.4% return over the last year and an impressive 76.6% gain across five years, Old National has shown that its long-term story is anything but boring. What is driving these swings?...

Paul Mueller (MUEL) posted a noteworthy turnaround in its recent earnings, swinging to profitability over the past year after a stretch of losses. Earnings have accelerated at an average annual rate of 41.3% over the last five years, and the company’s net profit margin has expanded as profitability returned. The latest data points to attractive value with shares trading below estimated fair value, but investors should keep an eye on the high proportion of non-cash earnings when weighing the...

Key Insights Audioboom Group's significant retail investors ownership suggests that the key decisions are influenced by...

If you’re wondering whether to keep holding, buy more, or finally part ways with Genpact, you’re not alone. The stock has been on a bit of a roller coaster, inviting both cautious observers and value hunters to the table. Over the past year, Genpact’s price has ticked up a respectable 4.5%, despite a choppy ride that includes a 6.4% dip over the past month and an overall 8.1% slide year-to-date. While that kind of short-term volatility might spook some investors, it can also mean opportunity,...

Dr. Ing. h.c. F. Porsche (XTRA:P911) saw net profit margins fall to 2.5% from 10.2% last year. This capped off another tough stretch in which earnings dropped by 9.2% per year on average over five years and remained negative year-on-year. Despite these pressures, the shares are trading at €47.16, below their estimated fair value of €63.43. Investors are tuning in for the promise of a 36.13% annualized earnings rebound over the next three years, which outpaces the broader German market. See...

If you’re thinking about whether Opera is a buy, sell, or just one to keep on your watchlist, you’re not alone. In the last week, the stock slipped by 3.2%, following a choppier month where it dropped 17.2%. That might make some investors uneasy, but if you zoom out, Opera’s story gets a lot more interesting. Despite the recent turbulence, the stock is still up a massive 356.5% over three years and 116.2% over the last five years. So, what’s driving these swings, and what could that mean for...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...